Skip to main content

Rheumatoid arthritis


04-03-2019 | Rheumatoid arthritis | Highlight | News

Sustained smoking cessation may reduce excess RA risk

Maintaining a nonsmoking status for a sustained period is associated with a reduction in the excess risk for developing seropositive rheumatoid arthritis, findings suggest.

25-02-2019 | Vaccination | Highlight | News

Immunogenicity of influenza vaccine confirmed in patients with rheumatic disease

Influenza vaccination gives rise to an adequate immune response among patients with rheumatic conditions, researchers report.

12-02-2019 | Cardiovascular disease | Editorial | Article

Cardiovascular risk management in arthritis: Why still a bridge too far?

Cardiovascular disease is the main cause of death in patients with rheumatoid arthritis. In this editorial Michael Nurmohamed discusses the EULAR recommendations for cardiovascular risk management, focusing on the role of the rheumatologist.

11-02-2019 | Rheumatoid arthritis | Editorial | Article

20 years of TNF inhibitors in rheumatoid arthritis

Understanding and treatment of rheumatoid arthritis has changed dramatically over the past two decades. Peter Taylor describes the impact of biologic tumor necrosis factor inhibitors on the management of this disease.

31-01-2019 | Rheumatoid arthritis | Highlight | News

Effectiveness of tocilizumab, rituximab over other biologics demonstrated

Patients with rheumatoid arthritis have better outcomes when treated with rituximab or tocilizumab than abatacept or tumor necrosis factor inhibitors, suggest the results from two real-world studies.

16-01-2019 | Rheumatoid arthritis | Highlight | News

Gene expression profiling points to methotrexate nonresponders

Rheumatoid arthritis patients who are unlikely to respond to methotrexate could be identified based on their gene expression profiles before and 4 weeks after initiating treatment, say researchers.

14-01-2019 | Rheumatoid arthritis | Highlight | News

Trial results support management of cardiovascular risk factors in RA patients

Managing traditional cardiovascular risk factors with a treat-to-target approach slows progression of subclinical atherosclerosis among patients with rheumatoid arthritis, suggest results from the FRANCIS trial.

20-12-2018 | Rheumatoid arthritis | Highlight | News

Serum calprotectin predicts relapse risk in TNFi-treated RA, PsA

Serum calprotectin levels independently predict relapse risk in tumor necrosis factor inhibitor-treated patients with rheumatoid arthritis or psoriatic arthritis who are in remission or have low disease activity, Spanish researchers report.

19-12-2018 | Diagnosis and screening | Podcast | Video

The importance of early diagnosis and treatment of inflammatory arthritis

In this Medicine Matters rheumatology podcast, we talk to President-Elect of EULAR Professor Iain McInnes, about the importance of early diagnosis and treatment of rheumatic diseases.

03-12-2018 | Rheumatoid arthritis | Highlight | News

Chronic opioid use rising in RA patients

Chronic opioid use among patients with rheumatoid arthritis increased substantially between 2002 and 2015, researchers report.

15-11-2018 | Etanercept biosimilar | Highlight | News

No worsening in disease activity with switch to biosimilar etanercept

Disease activity does not change following the switch from etanercept to the biosimilar formulation SB4, and treatment retention rates may be determined by patient-specific factors, suggests an analysis of the DANBIO registry.

14-11-2018 | Infection | Editorial | Article

Minimizing infection risk with biologic therapy

While the development of biologics has revolutionized treatment of rheumatic diseases, these agents can lead to immunosuppression and increased infection risk. Eoin Feeney discusses the role of screening and treatment for latent infection prior to therapy, vaccination timing, and travel risks in patients taking these medications.

29-10-2018 | Rheumatoid arthritis | ACR/ARHP 2018 | News

Peficitinib may be a promising treatment option for RA

Findings from two phase III trials presented at the 2018 ACR/ARHP Annual Meeting in Chicago, Illinois, USA, demonstrate that treatment with the JAK inhibitor peficitinib may be beneficial for patients with rheumatoid arthritis.

21-10-2018 | Rheumatoid arthritis | ACR/ARHP 2018 | News

High-dose influenza vaccine enhances immune response in RA patients

Administration of a high-dose influenza vaccine results in an improved humoral immune response when given to patients with rheumatoid arthritis, suggest findings from a randomized controlled trial.

18-10-2018 | Microbiome | Editorial | Article

Why every rheumatologist should understand the microbiome

James Rosenbaum and Mark Asquith discuss how the microbiome interacts with the immune system, how this may induce inflammation, and how the microbiome could be used as a therapeutic target for rheumatic diseases.

10-10-2018 | Mental health | Editorial | Article

Why depression and anxiety matter in patients with inflammatory arthritis

Advisory Board member Susan Bartlett discusses the prevalence of mental health comorbidities in patients with inflammatory arthritis, and their impact on disease symptoms and quality of life.

17-09-2018 | Rheumatoid arthritis | Highlight | News

No increased risk for CVD events with tocilizumab over other RA biologic DMARDs

Tocilizumab has a cardiovascular disease risk comparable with that of etanercept and other biologic DMARDs in individuals with rheumatoid arthritis, according to findings from a large, retrospective cohort study using real-world data.

07-09-2018 | Treatment | Feature | Article

At a glance: Common scores used in rheumatology

A quick-reference guide to the scores that are commonly used in clinical trials and daily rheumatology practice.

06-09-2018 | Pregnancy | Highlight | News

Increased risk for preterm delivery in women with RA and JIA

Women with rheumatoid arthritis and those with juvenile idiopathic arthritis have a significantly elevated risk for preterm delivery, according to a prospective cohort study published in Arthritis Care & Research.

05-09-2018 | Rheumatoid arthritis | Highlight | News

Biosimilar infliximab may not reduce treatment costs for US patients

Using infliximab-dyyb instead of the reference product may not reduce out-of-pocket costs for US rheumatoid arthritis patients insured on the Medicare Part D system, study results suggest.

image credits